Role of F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?

Date publication

octobre 2024

Journal

British journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ENTZ-WERLE Natacha , Dr RIOS Maria

Tous les auteurs :
Jehanno N, Corradini N, Gaspar N, Brahmi M, Valentin T, Revon Rivière G, Lervat C, Probert J, Entz-Werle N, Mansuy L, Plantaz D, Rios M, Saumet L, Verité C, Castex MP, Thebaud E, Cassou-Mounat T, Plissonnier AS, Mosseri V, Cordero C, Laurence V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39379569

Résumé

The Ewing Sarcoma Family of Tumors (ESFT) constitutes a group of rare malignancies, wherein approximately one-third of cases exhibit metastatic spread, particularly impacting prognosis when bone and/or bone marrow (BM) are involved. Primary extra-pulmonary metastatic ESFT often necessitates intensified therapeutic approaches. Accurate staging plays a pivotal role in clinical decision-making, with fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) currently serving as a non-invasive modality for assessing ESFT's BM extent.

Référence

Br J Cancer. 2024 10 8;: